Boundless Bio, Inc. (BOLD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Boundless Bio reported revenue of $0. Net income was -$58.2M, or -$2.60 per diluted share. Operating activities generated -$46.7M of cash, leaving -$47.2M of free cash flow. At fiscal year end, Boundless Bio held $157.1M in total assets against $58.4M in total liabilities, including $17.9M of cash and equivalents.
Open the full interactive Boundless Bio financials → Quarterly statements, key ratios, valuation history and price charts.
Boundless Bio Key Stats
| Share Price | $2.43 |
|---|---|
| Market Cap | $54.6M |
| 52-Week Range | $1.05 – $3.00 |
| Shares Outstanding | 22.4 million (basic, 2026 Q2) |
Boundless Bio Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Income | -$73.3M | -$63.6M |
| Pre-Tax Income | -$65.4M | -$58.2M |
| Income Tax | — | $0 |
| Net Income | -$65.4M | -$58.2M |
| Diluted EPS | -$3.85 | -$2.60 |
Boundless Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$13.9M | -$12.9M | -$13.6M | -$23.7M |
| Diluted EPS | -$0.62 | -$0.58 | -$0.60 | -$1.06 |
Boundless Bio Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $26.6M | $17.9M |
| Current Assets | $154.4M | $109.6M |
| Total Assets | $206.4M | $157.1M |
| Current Liabilities | $8.1M | $12.5M |
| Total Liabilities | $55.8M | $58.4M |
| Shareholders' Equity | $150.6M | $98.7M |
Boundless Bio Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$60.8M | -$46.7M |
| Cash From Investing | -$26.1M | $37.8M |
| Cash From Financing | $89.8M | $141,000 |
| Free Cash Flow | -$63.3M | -$47.2M |
Figures from Boundless Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Boundless Bio financials page for every line item.
Boundless Bio Company Profile
| Ticker | BOLD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | La Jolla, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001782303 |
Frequently Asked Questions
What was Boundless Bio's revenue in fiscal 2025?
Boundless Bio (BOLD) reported revenue of $0 for fiscal 2025.
What was Boundless Bio's net income in fiscal 2025?
Boundless Bio reported net income of -$58.2M for fiscal 2025.
What was Boundless Bio's earnings per share (EPS) in fiscal 2025?
Boundless Bio's diluted EPS was -$2.60 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Boundless Bio generate in fiscal 2025?
Boundless Bio generated -$47.2M of free cash flow in fiscal 2025.
What was Boundless Bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), Boundless Bio reported revenue of $0.
How many shares of Boundless Bio are outstanding?
Boundless Bio reported a weighted average of 22.4 million basic shares outstanding in 2026 Q2.
What is Boundless Bio's market cap?
Based on its latest closing price, Boundless Bio (BOLD) has a market capitalization of about $54.6M.
When does Boundless Bio's fiscal year end?
Boundless Bio's fiscal year end, as registered with the SEC, is December 31.
Where is Boundless Bio headquartered?
Boundless Bio lists its business address in La Jolla, California in its SEC filings.